PubRank

Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27313282)

Published in Circ Cardiovasc Interv on June 01, 2016

Authors

Muthiah Vaduganathan1, Robert A Harrington1, Gregg W Stone1, Ph Gabriel Steg1, C Michael Gibson1, Christian W Hamm1, Matthew J Price1, Jayne Prats1, Efthymios N Deliargyris1, Kenneth W Mahaffey1, Harvey D White1, Deepak L Bhatt2

Author Affiliations

1: From the Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA (M.V., D.L.B); Stanford University Medical School, CA (R.A.H., K.W.M.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York City, NY (G.W.S.); FACT (French Alliance for Cardiovascular clinical Trials), DHU FIRE, INSERM Unité 1148, Université Paris-Diderot, and Hôpital Bichat, Assistance-Publique-Hôpitaux de Paris, France, and NHLI, Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., E.N.D.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W).
2: From the Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA (M.V., D.L.B); Stanford University Medical School, CA (R.A.H., K.W.M.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York City, NY (G.W.S.); FACT (French Alliance for Cardiovascular clinical Trials), DHU FIRE, INSERM Unité 1148, Université Paris-Diderot, and Hôpital Bichat, Assistance-Publique-Hôpitaux de Paris, France, and NHLI, Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., E.N.D.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W). dlbhattmd@post.harvard.edu.

Associated clinical trials:

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX) (CHAMPION) | NCT01156571

Articles cited by this ↗

Universal definition of myocardial infarction. Circulation (2007) 11.69

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31

Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16

The anatomy of medical research: US and international comparisons. JAMA (2015) 3.93

Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol (2012) 1.64

Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial. EuroIntervention (2013) 1.41

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation (2011) 1.33

Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registry. Am Heart J (2014) 1.13

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J (2012) 1.05

Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol (2013) 1.03

International differences in treatment effect: do they really exist and why? Eur Heart J (2013) 0.92

Inter-regional differences in acute coronary syndrome trials. Eur Heart J (2000) 0.91

Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther (2013) 0.81

Are adverse events following an invasive strategy in patients with non-ST-segment elevation acute coronary syndromes more frequent at US sites versus non-US sites? Analysis from the ACUITY trial. Catheter Cardiovasc Interv (2013) 0.79

Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. Int J Cardiol (2010) 0.78

Are all clinical trial sites created equal? J Am Coll Cardiol (2012) 0.78